| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
146,000,000 |
| Market
Cap: |
16.60(B) |
| Last
Volume: |
2,843,953 |
Avg
Vol: |
1,347,527 |
| 52
Week Range: |
$92.79 - $209.935 |
|
| Level
I Sector: |
Information Technology |
| Level
II Sector: |
Electronics |
| Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11.4 |
| Insider 3/6 Months : 12 |
|
| Guru Rank Number : 691 |
| Guru Rank Value : 2.3 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
7,330 |
7,330 |
7,330 |
| Total Buy Value |
$0 |
$991,672 |
$991,672 |
$991,672 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
1,815 |
22,740 |
| Total Sell Value |
$0 |
$0 |
$314,105 |
$4,648,975 |
| Total People Sold |
0 |
0 |
2 |
3 |
| Total Sell Transactions |
0 |
0 |
4 |
17 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tousi Susan H |
SVP Product Development |
• • – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
694 |
42,615 |
|
- |
|
| Flatley Jay T |
Director |
• • – |
2021-02-16 |
4 |
AS |
$494.67 |
$247,543 |
I/I |
(500) |
3,500 |
|
-4% |
|
| Flatley Jay T |
Director |
• • – |
2021-02-16 |
4 |
AS |
$505.26 |
$2,021,040 |
D/D |
(4,000) |
172,933 |
|
-4% |
|
| Desouza Francis A |
President and CEO |
• • – |
2021-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
6,112 |
58,715 |
|
- |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
2,208 |
41,921 |
|
- |
|
| Aravanis Alexander |
SVP, Chief Technology Officer |
• • – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
2,208 |
5,503 |
|
- |
|
| Hoyt Aimee L |
SVP, Chief People Officer |
• • – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,380 |
3,739 |
|
- |
|
| Febbo Phillip G. |
SVP Chief Medical Officer |
• • – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,380 |
3,523 |
|
- |
|
| Ragusa Robert P |
SVP, Global Quality & Ops |
• • – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,656 |
5,795 |
|
- |
|
| Dadswell Charles |
SVP & General Counsel |
• • – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,380 |
4,892 |
|
- |
|
| Goswami Joydeep |
SVP Corp Business Development |
• • – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,380 |
4,112 |
|
- |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,380 |
4,494 |
|
- |
|
| Reeves Kathryne Gambrell |
SVP, Chief Marketing Officer |
• • – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,380 |
2,567 |
|
- |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2021-02-05 |
4 |
AS |
$431.90 |
$345,520 |
D/D |
(800) |
39,713 |
|
6% |
|
| Flatley Jay T |
Director |
• • – |
2021-02-02 |
4 |
AS |
$444.84 |
$1,779,360 |
D/D |
(4,000) |
176,933 |
|
3% |
|
| Mcginnis Karen K |
VP, Chief Accounting Officer |
• • – |
2021-02-02 |
4 |
AS |
$444.84 |
$32,028 |
D/D |
(72) |
1,538 |
|
3% |
|
| Hoyt Aimee L |
SVP, Chief People Officer |
• • – |
2021-02-02 |
4 |
AS |
$444.84 |
$25,356 |
D/D |
(57) |
2,359 |
|
3% |
|
| Desouza Francis A |
President and CEO |
• • – |
2021-02-01 |
4 |
AS |
$431.50 |
$1,319,330 |
D/D |
(3,000) |
52,603 |
|
2% |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2021-01-20 |
4 |
AS |
$400.00 |
$1,000,000 |
D/D |
(2,500) |
40,447 |
|
1% |
|
| Flatley Jay T |
Director |
• • – |
2021-01-19 |
4 |
AS |
$382.48 |
$1,529,920 |
D/D |
(4,000) |
180,933 |
|
4% |
|
| Hoyt Aimee L |
SVP, Chief People Officer |
• • – |
2021-01-11 |
4 |
AS |
$379.65 |
$102,885 |
D/D |
(271) |
2,359 |
|
6% |
|
| Hoyt Aimee L |
SVP, Chief People Officer |
• • – |
2021-01-08 |
4 |
D |
$379.61 |
$43,276 |
D/D |
(114) |
2,630 |
|
- |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2021-01-06 |
4 |
D |
$376.55 |
$80,582 |
D/D |
(214) |
3,114 |
|
- |
|
| Flatley Jay T |
Director |
• • – |
2021-01-05 |
4 |
AS |
$365.27 |
$1,461,080 |
D/D |
(4,000) |
184,933 |
|
2% |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2021-01-05 |
4 |
AS |
$365.27 |
$109,581 |
D/D |
(300) |
42,947 |
|
2% |
|
1655 Records found
|
|
Page 11 of 67 |
|
|
1.02 (0.88%) 
